USPTO Examiner PAK YONG D - Art Unit 1652

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18744124PHOTOSYSTEM I-HYDROGENASE CHIMERAS FOR HYDROGEN PRODUCTIONJune 2024March 2026Allow2111NoNo
18657159Heat Resistant Biopesticide And A Method Of Preparing The SameMay 2024June 2025Allow1321YesNo
18657101ENGINEERED GALACTOSE OXIDASE VARIANT ENZYMESMay 2024July 2025Allow1511NoNo
18655701PEROXIDASE ACTIVITY TOWARDS 10-ACETYL-3,7-DIHYDROXYPHENOXAZINEMay 2024October 2025Allow1721YesNo
18638690BETA-GLYCOSIDASE SS-BGL MUTANT FOR MODIFYING GINSENOSIDE AND APPLICATION THEREOFApril 2024January 2025Allow921NoNo
18611058Bacterium And Obtaining Method And Application ThereofMarch 2024January 2026Allow2221NoNo
18598466Cleaning Compositions Comprising EnzymesMarch 2024January 2026Abandon2221YesNo
18598872PROTEASE COMPOSITIONS AND METHODS OF USE THEREOFMarch 2024October 2025Abandon1911NoNo
18590655LACHNOSPIRACEAE SP. CAS12A MUTANTS WITH ENHANCED CLEAVAGE ACTIVITY AT NON-CANONICAL TTTT PROTOSPACER ADJACENT MOTIFSFebruary 2024August 2025Allow1821YesNo
18436552FEED COMPOSITION SUPPLEMENTED WITH A PROTEASE COMBINATIONFebruary 2024April 2025Abandon1401NoNo
18424815ENGINEERED STABLE NUCLEIC ACID-GUIDED NUCLEASESJanuary 2024September 2024Abandon711NoNo
18411153LIQUID FORMULATION OF ALPHA-AMYLASEJanuary 2024May 2025Abandon1701NoNo
18403265ENGINEERED URIDINE PHOSPHORYLASE VARIANT ENZYMESJanuary 2024June 2025Allow1711NoNo
18503542ENGINEERED DEOXYRIBOSE-PHOSPHATE ALDOLASESNovember 2023July 2025Allow2021NoNo
18504010TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE VARIANTS AND USES THEREOFNovember 2023June 2025Allow1921YesNo
18497758VARIANTS OF CHYMOSIN WITH IMPROVED MILK-CLOTTING PROPERTIESOctober 2023August 2025Abandon2221NoNo
18553072ENZYMATIC METHOD FOR PRODUCING L-GLUFOSINATE AND ITS PHOSPHOESTERSSeptember 2023September 2024Allow1221YesNo
18465961ENCAPSULATION OF DUAL-ENZYME COMPOSITION FOR PREVENTING, TREATING AND/OR ALLEVIATING VEISALGIA AND SYMPTOMS ASSOCIATED THEREWITHSeptember 2023October 2024Allow1311YesNo
18459797ENGINEERED TRANSAMINASE POLYPEPTIDESSeptember 2023February 2025Allow1711YesNo
18274770METHOD AND SPECIAL COMPLEX ENZYME FOR HYDROLYZING GALACTOMANNAN (GM) TO PREPARE SMALL-MOLECULE GM AND GALACTOMANNAN OLIGOSACCHARIDE (GMOS)July 2023April 2024Allow911YesNo
18341792GDSL LIPASE, GENETICALLY-ENGINEERED BACTERIA AND APPLICATION THEREOFJune 2023January 2025Allow1920YesNo
18039688METHODS FOR THE PURIFICATION OF REFOLDED FC-PEPTIDE FUSION PROTEINMay 2023November 2025Allow2910NoNo
18316993PRENYLTRANSFERASE VARIANTS AND METHODS FOR PRODUCTION OF PRENYLATED AROMATIC COMPOUNDSMay 2023November 2025Abandon3001NoNo
18300251METHOD OF IMPROVING ACID DECARBOXYLASE ACTIVITY IN VITRO UNDER ALKALINE PHApril 2023March 2025Allow2311NoNo
18031036METHOD OF PURIFICATION OF RECOMBINANTLY-PRODUCED RSV PROTEINS IN TRIMERIC FORMApril 2023March 2026Allow3510NoNo
18247957MUTATIONS FOR IMPROVING ACTIVITY AND THERMOSTABILITY OF PETASE ENZYMESApril 2023February 2026Allow3511NoNo
18123840RECOMBINANT HOST CELLS FOR THE PRODUCTION OF MALONATEMarch 2023August 2025Abandon2911NoNo
18245378NOVEL SERINE PROTEASESMarch 2023February 2026Abandon3501NoNo
18022429SYSTEMS, DEVICES AND METHODS FOR DETERMINING MOST PROBABLE NUMBER IN BIOLOGICAL SAMPLE ANALYSISFebruary 2023October 2025Allow3110NoNo
18006563CARBON MONOXIDE DEHYDROGENASE HAVING EXCELLENT OXYGEN RESISTANCE AND ENZYME ACTIVITY, AND USE THEREOFJanuary 2023September 2025Allow3110NoNo
18157226METHOD FOR PRODUCING HYDROXY-L-PIPECOLIC ACIDJanuary 2023October 2024Allow2121YesNo
18154475ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDESJanuary 2023April 2024Abandon1501NoNo
18154388ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDESJanuary 2023May 2024Abandon1601YesNo
18004327METHOD FOR THE FERMENTATIVE PRODUCTION OF GUANIDINOACETIC ACIDJanuary 2023April 2024Allow1630YesNo
18091687NOVEL HYDROLASE AND METHOD FOR PRODUCING (1S,2S)-1-ALKOXYCARBONYL-2-VINYLCYCLOPROPANE CARBOXYLIC ACID USING SAMEDecember 2022November 2024Allow2311YesNo
18087169APPLYING OPTOGENETIC AMPLIFIER CIRCUITS FOR MULTI-PHASE LIGHT CONTROLLED MICROBIAL FERMENTATIONSDecember 2022September 2025Allow3311NoNo
18066303FUCOSYLATION-DEFICIENT CELLSDecember 2022March 2024Allow1511NoNo
18063732Thermobifida fusca cutinase mutant and its soluble expression methodDecember 2022March 2026Abandon3911NoNo
18050446VARIANTS OF PORCINE TRYPSINOctober 2022November 2023Allow1301YesNo
18049055RECOMBINANT YEAST HOST CELL EXPRESSING AN HYDROLASEOctober 2022March 2024Abandon1711NoNo
18047824COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE VARIANTS AND METHODS OF USING COMPOSITIONS THEREOFOctober 2022January 2025Abandon2711NoNo
18046895ENGINEERED DNA POLYMERASE VARIANTSOctober 2022June 2024Allow2011NoNo
17916695METHODS FOR PRODUCTION OF OLIGOSACCHARIDESOctober 2022January 2026Abandon4001NoNo
17916510CARBOXYESTERASE POLYPEPTIDES FOR KINETIC RESOLUTIONSeptember 2022December 2025Allow3911YesNo
17936744NUCLEIC ACID POLYMERASE VARIANTS, KITS AND METHODS FOR TEMPLATE-INDEPENDENT RNA SYNTHESISSeptember 2022June 2025Abandon3311NoNo
17936610MUTATED SULFOTRANSFERASES AND USES THEREOFSeptember 2022June 2025Abandon3221NoNo
17934003BACILLUS SUBTILIS SUBSPECIESSeptember 2022January 2026Abandon4020NoYes
17947195DUAL-ENZYME COMPOSITION FOR PREVENTING, TREATING AND/OR ALLEVIATING VEISALGIA AND SYMPTOMS ASSOCIATED THEREWITHSeptember 2022July 2023Allow1020NoNo
17932184GENE RECOMBINANT VECTOR, GENETICALLY ENGINEERED STRAIN AND PREPARATION METHOD OF COLLAGENASESeptember 2022June 2023Allow910YesNo
17931003ENGINEERED GALACTOSE OXIDASE VARIANT ENZYMESSeptember 2022February 2024Allow1721NoNo
17929173XYLANASES FOR SOLUBILISING ARABINOXYLAN-CONTAINING MATERIALSeptember 2022January 2024Allow1621NoNo
17822587BLENDS CONTAINING PROTEASESAugust 2022January 2026Allow6021NoNo
17891482ENGINEERED CYANOBACTERIA WITH ENHANCED UV TOLERANCEAugust 2022February 2025Allow3021YesNo
17799049MANNANASE VARIANTSAugust 2022January 2026Allow4121YesNo
17818270RECOMBINANT YEAST EXPRESSING HETEROLOGOUS STL1 PROTEINAugust 2022July 2023Abandon1110NoNo
17879663Materials and Methods for Producing AlkaloidsAugust 2022June 2024Allow2211NoNo
17878858BIOSYNTHETIC PRODUCTION OF PSILOCYBIN AND RELATED INTERMEDIATES IN RECOMBINANT ORGANISMSAugust 2022July 2024Abandon2311NoNo
17811933METHOD FOR PRODUCING TREHALOSE EMPLOYING A TREHALOSE PHOSPHORYLASE VARIANTJuly 2022June 2025Allow3511NoNo
17811776METHODS AND MICROORGANISMS FOR THE FERMENTATION OF METHANE TO MULTI-CARBON COMPOUNDSJuly 2022October 2024Allow2721YesNo
17811801Cleaning Compositions comprising EnzymesJuly 2022September 2023Abandon1501NoNo
17811701Cleaning Compositions comprising EnzymesJuly 2022February 2024Allow1921YesNo
17811447Novel Selection Marker for Cell Transfection and Protein ProductionJuly 2022September 2024Allow2631YesNo
17852836Isolated or Engineered Polypeptides, Microorganisms as well as Method for Synthesizing Phenolic Phytochemical Phosphate Derivatives using the Polypeptides or MicroorganismsJune 2022May 2025Abandon3531YesNo
17758042RECOMBINANT BACTERIA FOR PRODUCING DE-EPOXIDIZED EPOTHILONE B AND USE THEREOFJune 2022September 2025Allow3811NoNo
17786720STABILIZATION OF OXIDASES BY DRYING UNDER REDUCED PARTIAL OXYGEN PRESSUREJune 2022January 2026Abandon4311NoNo
17784775MICROORGANISM COMPRISING VARIANT LYSE AND METHOD OF L-AMINO ACID PRODUCTION USING SAMEJune 2022October 2025Allow4021YesNo
17833695MICROORGANISMS AND METHODS FOR ENHANCING THE AVAILABILITY OF REDUCING EQUIVALENTS IN THE PRESENCE OF METHANOL, AND FOR PRODUCING 3-HYDROXYISOBUTYRATE OR METHACRYLIC ACID RELATED THERETOJune 2022July 2025Abandon3701NoNo
17832562USE OF GLUTAMINE SYNTHETASE FOR TREATING HYPERAMMONEMIAJune 2022November 2023Allow1730YesNo
17832564USE OF GLUTAMINE SYNTHETASE FOR TREATING HYPERAMMONEMIAJune 2022February 2025Allow3250YesNo
17779642METHODS OF REDUCING BIURET IN UREA COMPOSITIONSMay 2022May 2025Abandon3501NoNo
17728359TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS, ASSOCIATED FORMULATIONS AND USES THEREOFApril 2022April 2024Abandon2320NoNo
17711993Advanced Production of Cannabinoids in YeastApril 2022March 2024Allow2421YesNo
17700109HIGH EFFICIENCY BASE EDITORS COMPRISING GAMMarch 2022October 2023Allow1911NoNo
17641802METHOD FOR PRODUCING THE SESQUITERPENE VIRIDIFLOROL WITH A FUNGAL ENZYMEMarch 2022June 2025Allow3911YesNo
17691018MAD NUCLEASESMarch 2022April 2025Allow3721YesNo
17640152METHODS FOR PRODUCING D-TRYPTOPHAN AND SUBSTITUTED D-TRYPTOPHANSMarch 2022December 2025Abandon4511NoNo
17635163PEROXIDASE ACTIVITY TOWARDS 10-ACETYL-3,7-DIHYDROXYPHENOXAZINEFebruary 2022November 2023Allow2111NoNo
17671001Bacterium And Obtaining Method And Application ThereofFebruary 2022December 2023Allow2221YesNo
17592869ENGINEERED DEOXYRIBOSE-PHOSPHATE ALDOLASESFebruary 2022August 2023Allow1811NoNo
17591514CELL-FREE PRODUCTION OF RIBONUCLEIC ACIDFebruary 2022October 2024Abandon3301NoNo
17649365HETEROLOGOUS PRODUCTION OF 10-METHYLSTEARIC ACID BY CELLS EXPRESSING RECOMBINANT METHYLTRANSFERASEJanuary 2022November 2024Abandon3411NoNo
17583269LIPASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAMEJanuary 2022March 2025Abandon3851NoNo
17578275Reverse Transcriptase Mutants with Increased Activity and ThermostabilityJanuary 2022October 2025Allow4521YesNo
17571413VARIANTS OF CHYMOSIN WITH IMPROVED MILK-CLOTTING PROPERTIESJanuary 2022July 2023Allow1811NoNo
17565684PHOTOSYSTEM I-HYDROGENASE CHIMERAS FOR HYDROGEN PRODUCTIONDecember 2021March 2024Allow2621YesNo
17566077METHODS FOR SAFE AND EFFECTIVE THROMBOLYSIS USING SEQUENTIAL ADMINISTRATION OF TISSUE PLASMINOGEN ACTIVATOR AND MUTANT PRO-UROKINASEDecember 2021December 2025Allow4721YesNo
17646437RECOMBINANT HOST CELLS FOR THE PRODUCTION OF MALONATEDecember 2021May 2023Abandon1601NoNo
17597231METHOD FOR PRODUCING CYSTEINE FROM GLUTATHIONEDecember 2021April 2025Allow4031YesNo
17559121METHOD FOR PRODUCING GALACTOOLIGOSACCHARIDEDecember 2021March 2023Allow1510YesNo
17558454T7 RNA POLYMERASE VARIANTSDecember 2021April 2024Allow2821NoNo
17556504Additional Endoglucanase Variants and MethodsDecember 2021January 2024Allow2521YesNo
17596878BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDSDecember 2021May 2025Allow4131NoNo
17555012ENGINEERED URIDINE PHOSPHORYLASE VARIANT ENZYMESDecember 2021October 2023Allow2211NoNo
17552076NOVEL DNA METHYLTRANSFERASEDecember 2021January 2024Abandon2520NoNo
17550212MULTI-SUBSTRATE METABOLISM FOR IMPROVING BIOMASS AND LIPID PRODUCTIONDecember 2021October 2023Allow2211NoNo
17547287COMPOSITIONS AND METHODS COMPRISING PROTEASE VARIANTSDecember 2021August 2024Allow3221NoNo
17543608OMEGA-TRANSAMINASE MUTANT OBTAINED BY DNA SYNTHETIC SHUFFLING COMBINED MUTATION AND USEDecember 2021September 2023Abandon2121YesNo
17616843METHODS FOR DECOUPLING YIELD AND PRODUCTIVITY OF A NON-CATABOLIC COMPOUND PRODUCED BY A HOST CELLDecember 2021May 2024Allow2911NoNo
17615856MUTATION OF AN ACYL-COA SYNTHASE FOR INCREASED TRIACYLGLYCEROL PRODUCTION IN MICROALGAEDecember 2021May 2025Abandon4201NoNo
17615807FUSION PROTEINS FOR IMPROVED ENZYME EXPRESSIONDecember 2021January 2024Abandon2501NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PAK, YONG D.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
5
(71.4%)
Examiner Reversed
2
(28.6%)
Reversal Percentile
44.1%
Lower than average

What This Means

With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
109
Allowed After Appeal Filing
35
(32.1%)
Not Allowed After Appeal Filing
74
(67.9%)
Filing Benefit Percentile
49.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 32.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PAK, YONG D - Prosecution Strategy Guide

Executive Summary

Examiner PAK, YONG D works in Art Unit 1652 and has examined 1,313 patent applications in our dataset. With an allowance rate of 66.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner PAK, YONG D's allowance rate of 66.4% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by PAK, YONG D receive 1.73 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PAK, YONG D is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +21.2% benefit to allowance rate for applications examined by PAK, YONG D. This interview benefit is in the 66% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.2% of applications are subsequently allowed. This success rate is in the 51% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 55.6% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 89.9% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 72.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 71.2% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.8% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.